OpenAI Launches GPT-Rosalind, a Frontier Model Purpose-Built for Biology and Drug Discovery
A new domain-specific reasoning model targets translational medicine and biological research, signaling OpenAI's push into vertical AI products.
OpenAI announced GPT-Rosalind on Thursday, describing it as a "frontier reasoning model built to support research across biology, drug discovery, and translational medicine," as @OpenAI posted. The model is named after Rosalind Franklin, the crystallographer whose X-ray diffraction work was critical to discovering the structure of DNA.
Unlock the full briefing
Get every story in today's briefing, the full archive, and the daily AI intelligence brief.
All stories today
Full archive
Daily brief
Cancel anytime. Payments powered by Stripe.